Cutaneous T cell lymphoma

R Dummer, MH Vermeer, JJ Scarisbrick… - Nature reviews Disease …, 2021 - nature.com
Primary cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of lymphomas
that present in the skin with no evidence of extracutaneous disease at the time of diagnosis …

[HTML][HTML] European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome–Update …

F Trautinger, J Eder, C Assaf, M Bagot, A Cozzio… - European journal of …, 2017 - Elsevier
In order to provide a common standard for the treatment of mycosis fungoides (MF) and
Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer …

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

YH Kim, M Bagot, L Pinter-Brown, AH Rook… - The lancet …, 2018 - thelancet.com
Background Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with
substantial morbidity and mortality in advanced disease stages. We compared the efficacy of …

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

D Phillips, M Matusiak, BR Gutierrez, SS Bhate… - Nature …, 2021 - nature.com
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective
treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically …

[HTML][HTML] Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

R Willemze, E Hodak, PL Zinzani, L Specht, M Ladetto… - Annals of …, 2018 - Elsevier
Primary cutaneous lymphomas (PCLs) are defined as non-Hodgkin lymphomas that present
in the skin with no evidence of extracutaneous disease at the time of diagnosis. After …

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

JJ Scarisbrick, P Quaglino, HM Prince… - British Journal of …, 2019 - Wiley Online Library
Background Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI
(PRO spective Cutaneous Lymphoma International Prognostic Index) study is a web‐based …

Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study

MS Khodadoust, AH Rook, P Porcu, F Foss… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To assess the efficacy of pembrolizumab in patients with advanced relapsed or
refractory mycosis fungoides (MF) or Sézary syndrome (SS). PATIENTS AND METHODS …

Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

A De Masson, M Beylot-Barry, C Ram-Wolff, JB Mear… - The Lancet, 2023 - thelancet.com
Background Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually
refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic …

[HTML][HTML] EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome–update 2023

J Latzka, C Assaf, M Bagot, A Cozzio, R Dummer… - European Journal of …, 2023 - Elsevier
On behalf of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) and
following up on earlier versions published in 2006 and 2017 this document provides an …

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

AC Hristov, T Tejasvi, RA Wilcox - American journal of …, 2023 - Wiley Online Library
Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐
cell neoplasms involving the skin, the majority of which may be classified as Mycosis …